Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Visit the company website

 

Bullboard - Investor Discussion Forum Voyageur Pharmaceuticals Ltd V.VM

Alternate Symbol(s):  VYYRF

Voyageur Pharmaceuticals Ltd. is a Canada-based company engaged in the development of barium and iodine Active Pharmaceutical Ingredients (API) and offers high-performance imaging contrast agents. The Company is focused on vertically integrating the barium and iodine contrast market, and aims at producing its own barium, iodine, and endo fullerenes. The Company’s products include SmoothX... see more

TSXV:VM - Post Discussion

Voyageur Pharmaceuticals Ltd > Big Boys on Defensive
View:
Post by biggdogg on Feb 16, 2023 2:58pm

Big Boys on Defensive

FDA Break a Monopoly? LMAO! They state that on their website, BUT REALLY? Just look at the vaccine fruad. FDA are a subsidiary of Big Pharma, no different than the CDC or HC. The fact that they made "all contrast a drug", to keep barium sulfate from being a device, means on thing, Voy is a threat to the big boys, Threats get bought. The management are driving forward in a complex business. They have the Big Boys on the defensive, lets see what happens with a new contrast molecule, the threat level will go up 10 fold if they create a new contrast that will take over the MRI and CT industry. When is this news coming out? Hope its soon, a company with a new drug, adds one more asset to their portfollio of many. How are new drug development programs valued in pharma industries? It seems like in the hudreds of millions if you look at all the biotech companies making new, UNPROVEN drugs.
This is going to go to the moon at some point, and if there are 200M shares out, it will make no difference to all the folks in at less than $0.20. Dilution is meaningless in this scenerio. Is a NASDAQ listing coming in the future? The FDA changing the device ruling by making a new LAW is the best thing to ever happen to Voyaguer!! Nothing is going to stop Voyaguer except a BIG FAT check.
Comment by whitenorth72 on Feb 16, 2023 6:12pm
Exactly what Bigdog said
Comment by postie1 on Feb 16, 2023 7:12pm
They are a threat and if there is a bid comes forward, we can hope for a bidding war as there is probably several companies that might be interested . Meanwhile I am waiting for financing news plus I would like to see the overburden between zones A & b drilled as that could make this deposit a whole lot bigger. DYDD
Comment by Sweeper on Feb 17, 2023 9:33am
I can't see a bidding war anytime soon. There's still no financing and FDA approval looks like it will take another 4-5 years.
Comment by Budd22 on Feb 17, 2023 12:09pm
FDA approval In 4-5 years? Lol explain. Company can apply after 6 month batch testing if everything goes well and they already have begun the process. It takes up to 120 days to be approved after submission.  Everything is slow with the government tho so I would give it til 1st Q 2024. 
The Market Update
{{currentVideo.title}} {{currentVideo.relativeTime}}
< Previous bulletin
Next bulletin >

At the Bell logo
A daily snapshot of everything
from market open to close.


Connect with V.VM

follow v.vm on


Voyageur Pharmaceuticals Deck 2024..

The Watchlist

Voyageur Pharmaceuticals | The Watchlist
{{currentVideo.videoCaption}}
< Previous Video {{moreVideoText}} Next Video >

Investment Opportunity

COMPELLING
VALUE PROPOSITION

  • Only pharmaceutical company in the world that owns long-term supply of barium and iodine
  • Natural barium and iodine resources meet increasingly limited global supply and risk
  • Multi-billion-dollar global market for contrast media
  • Poised to obtain significant market share by offering high-quality, lower-cost products
  • Favorable regulatory pathway allows rapid commercialization
  • Highly experienced team has positioned the company for profitable commercial success

Contact Us

Brent Willis, CEO
Brent@Vpharma.ca

Address:
Suite 1600 Dome Tower, 333 7th Avenue S.W.
Calgary, Alberta
T2P 2Z1